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Abstract
Background: Concurrent chemotherapy and radiation is the standard treatment for unresectable stage III Lung
adenocarcinoma. However, no optimal concurrent chemotherapeutic regimen has been described. This study
aimed to assess concurrent pemetrexed, nedaplatin and thoracic intensity-modulated radiotherapy followed by
consolidation pemetrexed/nedaplatin for unresectable Stage IIIA/B lung adenocarcinoma.
Methods: Patients with unresectable stage III lung adenocarcinoma received thoracic intensity-modulated
radiotherapy at 60–64 Gy in 30–32 fractions, concurrently with two cycles of 500 mg/m2 pemetrexed, with
nedaplatin doses escalating from 60 mg/m2 (level 1) to 70 mg/m2 (level 2) and 80 mg/m2 (level 3). Consolidation
consisted of three pemetrexed/nedaplatin (500 mg/m2, 60 mg/m2) cycles every 3 weeks after concurrent therapy.
The primary objective of the safety was to determine the maximum-tolerated dose (MTD). The secondary endpoints
included response rate, PFS and OS.
Results: Fifteen patients were enrolled, including 3, 6 and 6 individuals in the first, second, and third dose levels,
respectively. Three cases of dose-limiting toxicities (grade 3 hepatitis, pneumonitis, and grade 4 thrombocytopenia),
including one and two patients at levels 2 and 3, respectively, were observed and resulted in discontinued/delayed
treatment. Response rates were 86.7 % (95 % confidence interval [CI], 64.2–97.8 %) and 64.3 % (95 % CI, 38.3–85.
4 %) at chemoradiation and treatment completions, respectively. Median OS was 30.0 months (95 % CI, 16.4–43.
6 months); 2-year OS was 44.0 % (95 % CI, 18.7–69.2 %). Median PFS was 12.0 months (95 % CI, 6.9–17.0 months),
and the 2-year PFS 27.0 % (95 % CI, 4.7–49.3 %).
Conclusions: Full dose 500 mg/m2 of pemetrexed and nedaplatin 70 mg/m2 could be used safely with thoracic
intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma. Further evaluation of stage III lung
adenocarcinoma management is warranted.
Trial registration: This study was retrospectively registered at Chinese Clinical Trial Registry (ChiCTR-OPN-16008316,
April 2016).
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Background
Approximately one third of all cancer-related deaths
are due to lung cancer, which accounts for more deaths
than breast, prostate, and colon cancer combined [1].
Non-small-cell lung cancer (NSCLC) accounts for ap-
proximately 80 % of all cases of lung cancer [2]. Adeno-
carcinoma and squamous cell carcinoma are the two
major subtypes of non-small cell lung carcinoma, with
~70 % of non-small cell lung carcinoma cases detected
at an unresectable stage [3]. Lung adenocarcinoma is
the most common type in females (smokers or non-
smokers) and non-smoking males; its percentage is higher
in Asia than in North America [4]. Concurrent chemora-
diotherapy is considered the standard of care for patients
with inoperable stages II and III disease [5, 6]. Full-dose
chemotherapy with concurrent chemoradiotherapy using
a platinum-based third-generation (i.e. paclitaxel, vinorel-
bine, and docetaxel) doublet results in unacceptable
toxicity [7]. Further studies to evaluate potential new che-
motherapeutic agents that have radiosensitizing potential
to pair with concurrent radiation, and can be used at
full dose with thoracic radiotherapy (TRT) for the
treatment of locally advanced non-small-cell lung
cancer (LA-NSCLC) are necessary to improve efficacy
[8]. Pemetrexed, an antifolate that inhibits multiple en-
zymes (thymidylate synthase, dihydrofolate reductase
and glycinamide ribonucleotide formyl transferase) in-
volved in purine and pyrimidine synthesis, has become
a drug of choice for patients with lung adenocarcinoma
[9, 10]. Nedaplatin is a second-generation platinum de-
rivative, which produces similar antitumor activities,
but causes less nausea/vomiting and nephrotoxicity
compared with cisplatin [11–14]. IMRT is an effective
technique with acceptable acute toxicity, also when
(sequentially or concomitantly) combined with chemo-
therapy [15]. Using IMRT to treat NSCLC leads to low
rates of pulmonary and esophageal toxicity, and favor-
able clinical outcomes in terms of survival [16]. The
combination of carboplatin/cisplatin, pemetrexed, and
TRT may not be the optimal regimen for locally advanced
patients. Therefore, a phase I study was designed to assess
the feasibility of a combination of concurrent nedaplatin,
pemetrexed and thoracic intensity-modulated, followed by
nedaplatin/pemetrexed consolidation without the dose
limiting toxicity (DLT) exceeding 33 % in patients with
inoperable Stage IIIA/B lung adenocarcinoma.
Methods
Patient eligibility
Patients with histologically or cytologically confirmed
adenocarcinoma stage IIIA/IIIB, deemed unresectable by
the Lung Cancer International Staging System, were eli-
gible. Each patient was a candidate for definitive radio-
therapy. Other eligibility criteria included the following:
measurable or assessable disease as defined by the
response evaluation criteria in solid tumours (RECIST)
criteria, performance status (PS) of 0 or 1, absolute neu-
trophil ≥2000 cells/μL, and platelet count ≥100,000/μL;
hemoglobin level ≥9 g/dL; calculated creatinine clear-
ance ≥60 mL/min; bilirubin level ≤2.0 mg/dL; trans-
aminase less than or equal to twice the upper limit of
the normal value; forced expiratory volume in 1 s >1.0 L.
Exclusion criteria comprised previous surgery, radiation
or chemotherapy; >5 % weight loss; clinically significant
medical or psychiatric disorders. Bone scan and com-
puted tomographic (CT) scans/magnetic resonance im-
aging of the chest, abdomen, and brain were performed.
All patients provided written informed consent and the
study was approved by the local ethics review board.
This study was retrospectively registered at Chinese
Clinical Trial Registry (ChiCTR-OPN-16008316, April
2016) after patient enrollment.
Treatment
The research protocol was approved by the ethics com-
mittee of the Nanhai Hospital of Southern Medical Uni-
versity. We also obtained the written consent of patients
for participation. This study was designed to determine
the possibility of administering concomitant pemetrexed/
nedaplatin chemotherapy and intensity-modulated radio-
therapy followed by pemetrexed/nedaplatin consolidation
chemotherapy for inoperable stage III lung adenocarcin-
oma without the DLT exceeding 33 % in the patients. The
secondary objectives included toxicity evaluation of
concurrent chemoradiation, consolidation treatment, and
complete treatment; assessment of response rate following
concomitant treatment and at treatment completion; de-
termination of overall and progression-free survival rates.
For chemotherapy, 500 mg/m2 Pemetrexed was admin-
istered i.v. on Days 1 and 22 in 250 mL normal saline
throughout levels 1–3, with premedication consisting of
dexamethasone, folic acid and vitamin B12. Nedaplatin
was administered by intravenous infusion for two concur-
rent cycles every 3 weeks. The dose of nedaplatin was es-
calated as follows: 60 mg/m2 (level 1), 70 mg/m2 (level 2),
and 80 mg/m2 (level 3). Consolidation treatment consisted
of three additional cycles of pemetrexed/nedaplatin
(500 mg/m2, 60 mg/m2) every 3 weeks after concurrent
therapy.
In the case of radiotherapy, IMRT (intensity-modulated
radiotherapy) was delivered to a cumulative dose of 60–
64 Gy at 2.0 Gy/fraction. Treatment planning was
based on CT simulation. The gross target volume
(GTV) included the primary tumor and involved lymph
nodes. Involved field irradiation, omitting elective ir-
radiation of lymph nodes, was used in order to optimize
definitive dosing to the tumor [17]. A clinical target vol-
ume (CTV) was defined around the GTV and subclinical
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lymph node regions using an expansion of 0.5–1.0 cm for
the presumed microscopic extension. A 0.7–0.8 cm mar-
gin was added to create an internal target volume (ITV).
The planning target volume (PTV) consisted of ITV with
the vertical field margins extended to 0.5–1.0 cm and lat-
eral field margins extended to 0.5 cm for setup variations.
Normal tissue constraints were as follows: the maximum
point dose to the spinal cord, 48 Gy; total lung, V5 < 65 %
and V20 < 35 %; mean lung dose, ≤20 Gy; heart, V30 <
50 %. IMRT plans were developed by using a commercial
treatment-planning system (XIO-Release 4.80, Elekta,
Ltd., Stockholm, Sweden).
Toxicity assessment and response
Toxicity was assessed using the National Cancer Institute
(NCI)’s Common Terminology Criteria for Adverse Events
(CTCAE).v4.03 [18]. Assessment of disease response was
carried out using the RECIST 1.1 criteria [19, 20] at
3 weeks after chemoradiation completion and a month
after consolidation therapy. The best overall response is
based on all tumor assessments starting from chemoradia-
tion. Then, restaging scans were performed every 3 months
for 1 year, and every 6 months from treatment end.
At least three patients were enrolled for each dose
level, and had to have completed concurrent adminis-
tration of nedaplatin/pemetrexed/radiotherapy without
Dose-limiting toxicities (DLT) before escalation to the
next dose. If 1 patient experienced DLT, 3 additional
patients were accrued. If no more than 1 of the 6 pa-
tients experienced DLT, the next three patients were
treated at the next higher dose level. If 2 out of 6 pa-
tients at a dose level experienced DLT, this level was
considered the maximum tolerated dose (MTD). DLT
were assessed during chemoradiation and up to 5 weeks
after consolidation completion. Dose-limiting toxicities
were defined from early and late toxicities as follows:
Grade 3/4 hematological toxicity, febrile neutropenia,
esophagitis, pneumonitis, or persistent elevation of
creatinine, bilirubin and transaminase resulting in pre-
venting treatment, or dosing delay because of toxicity
(radiation therapy was delayed by a week or more; the
following chemotherapy was delayed by 2 weeks or
more, while consolidation therapy was delayed by
4 weeks or more after radiotherapy completion), or late
high-grade (>3) bronchopulmonary and esophageal tox-
icities according to criteria of the Radiation Therapy
Oncology Group (RTOG).
Statistical analyses
Quantitative variables were described as median and
standard deviation (SD). A potential follow-up of at least
24 months was required for analysis. Survival was defined
as the time from the first day of treatment to death or last
follow-up. Progression-free survival was measured from
the first day of treatment to the time of disease pro-
gression. Overall and progression-free survival rates
were estimated using the Kaplan-Meier method [21].
xStatistical analyses were performed using SPSS for
Windows version 16.0.
Results
Between January 2012 and September 2013, 15 patients
were enrolled in this study at the Nanhai Hospital of
Southern Medical University and the Cancer Center of
Guangzhou Medical University. The demographic char-
acteristics of patients are shown in Table 1.
At the Level 1 dose, 1 of the first 3 patients experi-
enced grade 3 esophagitis and grade 2 neutropenia dur-
ing the second cycle; because no DLT was observed at
Level 1, nedaplatin dose was escalated to Level 2. One
patient receiving Level 2 dose, with hepatitis B virus,
developed viral hepatitis that resulted in grade 3 trans-
aminase, and discontinued consolidation therapy after 2
concurrent chemotherapy cycles and full-dose radi-
ation. More than 30 % of patients developed grade 3/4
neutropenia on Dose Level 3. One patient developed
grade 4 thrombocytopenia and another experienced
grade 3 pneumonitis that lasted at least a week, which
were considered DLTs. Esophagus toxicity other than
hematological toxicity was well tolerated. All patients
completed irradiation (60–64Gy) as prescribed (Table 2).
Delay of scheduled radiation therapy owing to esophagitis
and pneumonitis occurred in only 2 patients (3 days and
1 week, respectively). The dose-volume histogram showed
that the V20 and mean lung dose (MLD) of these patients









Median (range) 59 (65–56) 61 (48–63) 63 (52–68) 62 (48–68)
Gender, n
Male 1 4 3 8 (53 %)
Female 2 2 3 7 (47 %)
ECOG performance status, n
0 2 2 2 6 (40 %)
1 1 4 4 9 (60 %)
Clinical stage
IIIA 1 2 2 5 (33 %)
IIIB 2 4 4 10 (67 %)
Smoking History, n
Never 2 2 3 7 (47 %)
Ever 1 4 3 8 (53 %)
Former 1 2 1 4 (27 %)
Current 0 2 2 4 (53 %)
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were 18–33 % and 926–1535 cGy, respectively. A total of
14 patients received consolidation therapy as planned.
Table 3 summarizes the grade 3/4 adverse events observed
during the chemoradiation and consolidation phases of
the study. Severe late toxicities (radiation pneumonitis,
prolonged esophagitis, or spinal cord toxicities) were
uncommon in all longterm survivors.
In this study, response rates were 86.7 % (95 % confi-
dence interval [CI], 64.2–97.8 %) and 80.0 % (95 % CI,
56.0–94.6 %) at chemoradiation end and treatment com-
pletion, respectively (Table 4). The median follow-up time
for the censored cases was 26.3 months. The median OS
was 30.0 months (95 % CI, 16.4 to 43.6 months), with a 3-
year OS rate of 44.0 % (95 % CI, 18.7 to 69.2 %). The me-
dian PFS was 12.0 months (95 % CI, 6.9 to 17.0 months),
with a 2-year PFS rate of 27.0 % (95 % CI, 4.7 to 49.3 %)
(Figs. 1, 2). Only 2 patients had PD, which resulted from
liver and contralateral lung metastases. DLTs were ob-
served in one of six patients at level 2, and two of six at
level 3. The DLTs observed were grade 3 hepatitis and
pneumonitis, and grade 4 thrombocytopenia. Dose-related
grade 3 esophagitis, neutropenia, and vomiting were
observed but were not dose-limiting. There was no late
toxicity greater than grade 3. The MTD was determined
to be level 3.
Discussion
A total of 30–40 % of NSCLC patients present with lo-
cally or regionally advanced unresectable tumors. But
the optimal regimen, dosage, and administered agents
for locally-advanced non-small-cell lung cancer remain
controversial. Radiation therapy (RT) combined with
chemotherapy is more effective than RT alone, and con-
comitant chemoradiation has yielded improved survival
compared to sequential chemotherapy and RT, but at
the cost of heightened toxicity, especially esophagitis
[22]. Current international guidelines recommend the
use of platinum-based chemotherapy and concurrent
thoracic radiotherapy (TRT) for patients with locally
advanced non-small-cell lung cancer (NSCLC). Peme-
trexed is considered to be less toxic than other cyto-
toxic agent. Previous studies have demonstrated that
full dose pemetrexed-based chemotherapy concurrently
with thoracic radiation therapy is feasible for NSCLC
patients with unresectable stage III disease [23, 24]. We
assessed the optimal dose, toxicity, and tolerability of
concurrent dose-escalation of nedaplatin/pemetrexed
with TRT followed by consolidation in patients with
unresectable locally advanced lung adenocarcinoma.
Nedaplatin, a second-generation cisplatin analog and
useful chemotherapeutic agent with radiosensitizing prop-
erties, has been developed to reduce cisplatin-induced
toxicities, especially in patients with NSCLC, esophageal
cancer, uterine cervical cancer, head and neck cancer, or
urothelial cancer [25]. It was approved for the treatment
of NSCLC, including adenocarcinoma and squamous car-
cinoma, in China. Teramoto et al. [12] reported a phase II
study of docetaxel plus nedaplatin in patients with meta-
static non-small-cell lung cancer. They found an overall
response rate of 50.0 %; median survival and median
progression-free survival times were 13.0 and 7.4 months,
Table 2 Radiotherapy delivery
Dose level N Radiation therapy dose (Gy) Dose delay due to AE
Level 1 3 62 62a 64 1 (3 days)
Level 2 6 64 60 62 0
64 62 60




Table 3 Grade 3–4 adverse events (CTCAE version 3.0, Concurrent
chemoradiotherapy course N = 15, Consolidation chemotherapy
course N = 14)




Neutropenia 5 (33.3) 2 (14.3)
Anemia 2 (13.3) 3 (21.4)
Thrombocytopenia 2 (13.3) 1 (7.1)
Febrile
neutropenia
1 (6.7) 0 (0.0)
Vomiting 2 (13.3) 0 (0.0)
Esophagitis 3 (20.0) 1 (7.1)
Transaminase 1 (6.7) 0 (0.0)
Pneumonitis 1 (6.7) 0 (0.0)
Creatinine 0 0 (0.0)
Table 4 Efficacy (RECIST version 1.1)
Study phase Response N %








CR complete response, PR partial response, SD stable disease, PD
progressive disease
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respectively. These findings indicate that the docetaxel
and nedaplatin combination is well tolerated with potent
activity in patients with metastatic NSCLC. Other phase II
studies assessed nedaplatin in combination with irinote-
can, gemcitabine and paclitaxel, respectively, used as first-
line chemotherapy, and reported response rates of 65.8 %,
45.7 % and 53.2 %, respectively, in patients with NSCLC
[26–28]. In unresectable stage IIIA or IIIB NSCLC indi-
cated for curative radiotherapy, Sekine et al. [29] reported
a phase I study of nedaplatin at 80 mg/m2 and escalating
doses of paclitaxel from 120 to 150 mg/m2 concurrently
with thoracic radiotherapy (TRT) in 18 patients. It was
concluded that paclitaxel and nedaplatin doses could not
be escalated due to severe pulmonary toxicity at level 1.
Another phase I/II trial of weekly paclitaxel (35 mg/m2)
and nedaplatin (20 mg/m2) for 6 weeks revealed that this
regimen is safe and effective for NSCLC with concurrent
TRT [30]. A phase II study led by Oshita et al. [31] evalu-
ated a dose of nedaplatin at 50 mg/m2, and irinotecan at
60 mg/m2 on days 1 and 8 every 4 weeks for 2–4 cycles
with concurrent TRT (2 Gy per day, totaling 60 Gy). This
treatment was effective and safe for patients, and 5-year
disease-free and overall survival rates were 25.7 % and
40.0 %, respectively. However, no Phase III study assessing
Fig. 1 Overall survival curve. MST, median survival time (N = 15)
Fig. 2 Progression-free survival (PFS) curve (N = 15)
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chemotherapy or concurrent chemoradiotherapy using
nedaplatin has been reported, because nedaplatin is not
commonly used throughout the world.
Pemetrexed, a novel, multi-targeted antifolate chemo-
therapy agent that inhibits target enzymes (thymidylate
synthase, dihydrofolate reductase, and glycinamide ribo-
nucleotide formyl transferase), was initially approved for
second-line treatment of advanced NSCLC [32]. Peme-
trexed was subsequently approved as first-line in ad-
vanced non-squamous NSCLC based on a phase III trial
showing a survival advantage for pemetrexed–cisplatin
compared to gemcitabine–cisplatin [33]. Pemetrexed
also is a feasible agent for concurrent chemoradiother-
apy and consolidation therapy [34, 35].
Intensity-modulated radiotherapy (IMRT) is an ad-
vanced radiotherapy that uses intensity-modulated beams,
which can provide multiple intensity levels for any single
beam direction and a given source position, allowing
shaped distributions and dose gradients with narrower
margins than previously possible [36]. In comparison with
3D-CRT, involved-field radiotherapy (IF-RT) and IMRT
combination leads to a significantly better sparing of nor-
mal tissues and higher total doses, while the potential
therapeutic drawback of decreased incidental irradiation
of elective lymph nodes is moderate [37].
Both agents have demonstrated safety and efficacy in
locally advanced non-small cell lung cancer in conjunc-
tion with Radiation therapy.
On the definition of Dose-limiting toxicities, there are
some difference among them because of the various
methods and theories. In most cases, DLTs were defined
as severe toxicity leading to dose reduction or treatment
discontinuation [38–40]. According to the criteria for
DLT in the protocol, we determine The MTD to be level
3 (nedaplatin 80 mg/m2) in this trial. The recommended
dose is to be the best tolerated dose immediately below
the MTD [41]. In the majority of the trials, the recom-
mended dose was usually defined as one dose level
below the MTD. But in some trials the recommended
dose was equivalent to the MTD. There was lack of
standardization, so we recommend the lower dose for
safety. This study identified the recommended nedapla-
tin dose at 70 mg/m2 for phase II evaluation. The dose
of chemotherapy in current study was lower than that in
a Japanese phase III study of 100 mg/m2 nedaplatin and
60 mg/m2 docetaxel, or 80 mg/m2 cisplatin and 60 mg/
m2 docetaxel for squamous cell lung cancer with stage
IIIB/IV or postoperative recurrence [42]. They showed
that OS (13.6 vs 11.4 months) was significantly longer in
the nedaplatin group, but grade 3 or worse leucopenia
(55 % vs 45 %), neutropenia (82 % vs 71 %), and
thrombocytopenia (9 % vs 0 %) were more frequent in
the nedaplatin group. Toxicity were more serious
compare to the outcome of this study. To avoid severe
adverse effects and interruption of radiationtherapy, ap-
propriate dose reduction would be feasible. Indeed, the
comparatively small sample size and short follow-up
time in the current investigation present limitations.
Future studies are warranted.
The response group was defined as patients achieving
a CR or PR. In the chemoradiation phase and treatment
completion, the response rate was 86.7 % and 80.0 %,
respectively. The majority of patients experienced PR
(thirteen patients) and two patients had SD in chemora-
diation phase. At completion of treatment three patients
had SD, in addition, one patient obtained CR and thir-
teen patients PR as their best overall tumour response.
Further more, two of the three patients had SD for at
least 6 months. The median OS was 30.0 months with a
3-year OS rate of 44.0 %. The median PFS was
12.0 months with a 2-year PFS rate of 27.0 %. Our re-
sults are consistent with previous studies. A phase I
study of pemetrexed plus cisplatin followed by peme-
trexed consolidation therapy with dose-escalation of
TRT in patients with locally advanced nonsquamous
NSCLC showed that the objective response rate was
83 %. A phase II study of pemetrexed plus cisplatin with
concurrent TRT in Stage IIIA or Stage IIIB non-
squamous NSCLC showed a best overall response of
72 %(PFS, 13.8 months; OS, 26.2 months) [43]. Further-
more, a randomized phase III study was performed to
investigate the effect of pemetrexed 500 mg/m2 + cis-
platin 75 mg/m2 or etoposide 50 mg/m2 + cisplatin
50 mg/m2 with plus concurrent TRT followed by peme-
trexed consolidation cytotoxic chemotherapy in locally
advanced nonsquamous NSCLC [44]. It shows that me-
dian PFS, ORR and disease control rate was respectively
11.4 months, 35.9 % and 80.7 % in the pemetrexed-
cisplatin group and 9.8 months, 33.0 % and 70.7 % in the
etoposide-cisplatin group. The Pem+Cis arm did not im-
prove PFS compared with the control arm, but had a
greater security.
Conclusions
In conclusion, the present phase I study is the first of its
kind assessing combination therapy by nedaplatin and
pemetrexed with thoracic intensity-modulated radio-
therapy for inoperable stage III lung adenocarcinoma.
The DLTs seen with this combination were hepatitis,
thrombocytopenia, febrile neutropenia, and pulmonary
toxicity. Preliminary local disease control and overall
survival are encouraging. Our findings suggest that full
dose 500 mg/m2 of pemetrexed and nedaplatin 70 mg/m2
could be used safely with thoracic intensity-modulated
radiotherapy for inoperable stage III lung adenocarcin-
oma.. The response rate, PFS, and overall survival are
encouraging. An ongoing phase II/III study is to evaluate
the efficacy of the same chemoradiation platform as the
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present trial or cisplatin and pemetrexed in patients with
unresectable stage III lung adenocarcinoma. Further
evaluation of stage III lung adenocarcinoma management
is required.
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